ABP-671 for Gout
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with gout who have been taking allopurinol daily for at least 14 days. Participants are divided into two groups based on kidney function: one with normal and another with moderate impairment.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ABP-671 in combination with stable Allopurinol therapy to evaluate pharmacokinetic interactions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABP-671
Trial Overview
The study tests how ABP-671 interacts with allopurinol in patients already using allopurinol for gout. It's an open-label trial, meaning everyone knows which drugs are given, and it measures the drug levels in the body.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Atom Therapeutics Co., Ltd
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.